Chemistry:Amenamevir
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Trade names | Amenalief |
Other names | ASP-2151, ASP2151 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C24H26N4O5S |
Molar mass | 482.56 g·mol−1 |
3D model (JSmol) | |
| |
|
Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).
It acts as an inhibitor of the zoster virus's helicase–primase complex.[1][2] Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]
References
- ↑ "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology 44 (11): 1219–1227. November 2017. doi:10.1111/1346-8138.13948. PMID 28681394.
- ↑ "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research 139: 95–101. March 2017. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917.
- ↑ "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017.
![]() | Original source: https://en.wikipedia.org/wiki/Amenamevir.
Read more |